Table of Contents
1 Report Overview
1.1 Research Scope
1.2 Top Neuroendocrine Carcinoma Drugs Manufacturers Covered: Ranking by Revenue
1.3 Market Segment by Type
1.3.1 Global Neuroendocrine Carcinoma Drugs Market Size by Type: 2015 VS 2020 VS 2026 (US$ Million)
1.3.2 Somatostatin Analogs
1.3.3 Targeted Therapy
1.3.4 Chemotherapy
1.4 Market Segment by Application
1.4.1 Global Neuroendocrine Carcinoma Drugs Consumption by Application: 2015 VS 2020 VS 2026
1.4.2 Hospital
1.4.3 Clinics
1.4.4 Oncology Centres
1.4.5 Ambulatory Surgery Centres
1.5 Study Objectives
1.6 Years Considered
2 Global Market Perspective
2.1 Global Neuroendocrine Carcinoma Drugs Revenue (2015-2026)
2.1.1 Global Neuroendocrine Carcinoma Drugs Revenue (2015-2026)
2.1.2 Global Neuroendocrine Carcinoma Drugs Sales (2015-2026)
2.2 Neuroendocrine Carcinoma Drugs Market Size across Key Geographies Worldwide: 2015 VS 2020 VS 2026
2.2.1 Global Neuroendocrine Carcinoma Drugs Sales by Regions (2015-2020)
2.2.2 Global Neuroendocrine Carcinoma Drugs Revenue by Regions (2015-2020)
2.3 Global Top Neuroendocrine Carcinoma Drugs Regions (Countries) Ranking by Market Size
2.4 Neuroendocrine Carcinoma Drugs Industry Trends
2.4.1 Neuroendocrine Carcinoma Drugs Market Top Trends
2.4.2 Market Drivers
2.4.3 Neuroendocrine Carcinoma Drugs Market Challenges
2.4.4 Porter’s Five Forces Analysis
2.4.5 Primary Interviews with Key Neuroendocrine Carcinoma Drugs Players: Views for Future
3 Competitive Landscape by Manufacturers
3.1 Global Top Neuroendocrine Carcinoma Drugs Manufacturers by Sales (2015-2020)
3.1.1 Global Neuroendocrine Carcinoma Drugs Sales by Manufacturers (2015-2020)
3.1.2 Global Neuroendocrine Carcinoma Drugs Sales Market Share by Manufacturers (2015-2020)
3.1.3 Global 5 and 10 Largest Manufacturers by Neuroendocrine Carcinoma Drugs Sales in 2019
3.2 Global Top Manufacturers Neuroendocrine Carcinoma Drugs by Revenue
3.2.1 Global Neuroendocrine Carcinoma Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Global Neuroendocrine Carcinoma Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Neuroendocrine Carcinoma Drugs Market Concentration Ratio (CR5 and HHI)
3.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neuroendocrine Carcinoma Drugs as of 2019)
3.4 Global Neuroendocrine Carcinoma Drugs Average Selling Price (ASP) by Manufacturers
3.5 Key Manufacturers Neuroendocrine Carcinoma Drugs Plants/Factories Distribution and Area Served
3.6 Date of Key Manufacturers Enter into Neuroendocrine Carcinoma Drugs Market
3.7 Key Manufacturers Neuroendocrine Carcinoma Drugs Product Offered
3.8 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Neuroendocrine Carcinoma Drugs Historic Market Review by Type (2015-2020)
4.1.2 Global Neuroendocrine Carcinoma Drugs Sales Market Share by Type (2015-2020)
4.1.3 Global Neuroendocrine Carcinoma Drugs Revenue Market Share by Type (2015-2020)
4.1.4 Neuroendocrine Carcinoma Drugs Price by Type (2015-2020)
4.1 Global Neuroendocrine Carcinoma Drugs Market Estimates and Forecasts by Type (2021-2026)
4.2.2 Global Neuroendocrine Carcinoma Drugs Sales Forecast by Type (2021-2026)
4.2.3 Global Neuroendocrine Carcinoma Drugs Revenue Forecast by Type (2021-2026)
4.2.4 Neuroendocrine Carcinoma Drugs Price Forecast by Type (2021-2026)
5 Global Neuroendocrine Carcinoma Drugs Market Size by Application
5.1 Global Neuroendocrine Carcinoma Drugs Historic Market Review by Application (2015-2020)
5.1.2 Global Neuroendocrine Carcinoma Drugs Sales Market Share by Application (2015-2020)
5.1.3 Global Neuroendocrine Carcinoma Drugs Revenue Market Share by Application (2015-2020)
5.1.4 Neuroendocrine Carcinoma Drugs Price by Application (2015-2020)
5.2 Global Neuroendocrine Carcinoma Drugs Market Estimates and Forecasts by Application (2021-2026)
5.2.2 Global Neuroendocrine Carcinoma Drugs Sales Forecast by Application (2021-2026)
5.2.3 Global Neuroendocrine Carcinoma Drugs Revenue Forecast by Application (2021-2026)
5.2.4 Neuroendocrine Carcinoma Drugs Price Forecast by Application (2021-2026)
6 North America
6.1 North America Neuroendocrine Carcinoma Drugs Breakdown Data by Company
6.2 North America Neuroendocrine Carcinoma Drugs Breakdown Data by Type
6.3 North America Neuroendocrine Carcinoma Drugs Breakdown Data by Application
6.4 North America Neuroendocrine Carcinoma Drugs Breakdown Data by Countries
6.4.1 North America Neuroendocrine Carcinoma Drugs Sales by Countries
6.4.2 North America Neuroendocrine Carcinoma Drugs Revenue by Countries
6.4.3 U.S.
6.4.4 Canada
7 Europe
7.1 Europe Neuroendocrine Carcinoma Drugs Breakdown Data by Company
7.2 Europe Neuroendocrine Carcinoma Drugs Breakdown Data by Type
7.3 Europe Neuroendocrine Carcinoma Drugs Breakdown Data by Application
7.4 Europe Neuroendocrine Carcinoma Drugs Breakdown Data by Countries
7.4.1 Europe Neuroendocrine Carcinoma Drugs Sales by Countries
7.4.2 Europe Neuroendocrine Carcinoma Drugs Revenue by Countries
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
8 Asia Pacific
8.1 Asia Pacific Neuroendocrine Carcinoma Drugs Breakdown Data by Company
8.2 Asia Pacific Neuroendocrine Carcinoma Drugs Breakdown Data by Type
8.3 Asia Pacific Neuroendocrine Carcinoma Drugs Breakdown Data by Application
8.4 Asia Pacific Neuroendocrine Carcinoma Drugs Breakdown Data by Regions
8.4.1 Asia Pacific Neuroendocrine Carcinoma Drugs Sales by Regions
8.4.2 Asia Pacific Neuroendocrine Carcinoma Drugs Revenue by Regions
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 India
8.4.7 Australia
8.4.8 Taiwan
8.4.9 Indonesia
8.4.10 Thailand
8.4.11 Malaysia
8.4.12 Philippines
8.4.13 Vietnam
9 Latin America
9.1 Latin America Neuroendocrine Carcinoma Drugs Breakdown Data by Company
9.2 Latin America Neuroendocrine Carcinoma Drugs Breakdown Data by Type
9.3 Latin America Neuroendocrine Carcinoma Drugs Breakdown Data by Application
9.4 Latin America Neuroendocrine Carcinoma Drugs Breakdown Data by Countries
9.4.1 Latin America Neuroendocrine Carcinoma Drugs Sales by Countries
9.4.2 Latin America Neuroendocrine Carcinoma Drugs Revenue by Countries
9.4.3 Mexico
9.4.4 Brazil
9.4.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Neuroendocrine Carcinoma Drugs Breakdown Data by Type
10.2 Middle East and Africa Neuroendocrine Carcinoma Drugs Breakdown Data by Application
10.3 Middle East and Africa Neuroendocrine Carcinoma Drugs Breakdown Data by Countries
10.3.1 Middle East and Africa Neuroendocrine Carcinoma Drugs Sales by Countries
10.3.2 Middle East and Africa Neuroendocrine Carcinoma Drugs Revenue by Countries
10.3.3 Turkey
10.3.4 Saudi Arabia
10.3.5 U.A.E
11 Company Profiles
11.1 Xiaflex
11.1.1 Xiaflex Corporation Information
11.1.2 Xiaflex Business Overview and Total Revenue (2019 VS 2018)
11.1.3 Xiaflex Neuroendocrine Carcinoma Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.1.4 Xiaflex Neuroendocrine Carcinoma Drugs Products and Services
11.1.5 Xiaflex SWOT Analysis
11.1.6 Xiaflex Recent Developments
11.2 Novartis AG
11.2.1 Novartis AG Corporation Information
11.2.2 Novartis AG Business Overview and Total Revenue (2019 VS 2018)
11.2.3 Novartis AG Neuroendocrine Carcinoma Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.2.4 Novartis AG Neuroendocrine Carcinoma Drugs Products and Services
11.2.5 Novartis AG SWOT Analysis
11.2.6 Novartis AG Recent Developments
11.3 Roche
11.3.1 Roche Corporation Information
11.3.2 Roche Business Overview and Total Revenue (2019 VS 2018)
11.3.3 Roche Neuroendocrine Carcinoma Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.3.4 Roche Neuroendocrine Carcinoma Drugs Products and Services
11.3.5 Roche SWOT Analysis
11.3.6 Roche Recent Developments
11.4 Molecular Insight pharmaceuticals
11.4.1 Molecular Insight pharmaceuticals Corporation Information
11.4.2 Molecular Insight pharmaceuticals Business Overview and Total Revenue (2019 VS 2018)
11.4.3 Molecular Insight pharmaceuticals Neuroendocrine Carcinoma Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.4.4 Molecular Insight pharmaceuticals Neuroendocrine Carcinoma Drugs Products and Services
11.4.5 Molecular Insight pharmaceuticals SWOT Analysis
11.4.6 Molecular Insight pharmaceuticals Recent Developments
11.5 Callisto Pharmaceuticals
11.5.1 Callisto Pharmaceuticals Corporation Information
11.5.2 Callisto Pharmaceuticals Business Overview and Total Revenue (2019 VS 2018)
11.5.3 Callisto Pharmaceuticals Neuroendocrine Carcinoma Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.5.4 Callisto Pharmaceuticals Neuroendocrine Carcinoma Drugs Products and Services
11.5.5 Callisto Pharmaceuticals SWOT Analysis
11.5.6 Callisto Pharmaceuticals Recent Developments
12 Supply Chain and Sales Channels Analysis
12.1 Supply Chain Analysis
12.2 Sales Channels Analysis
12.2.1 Neuroendocrine Carcinoma Drugs Sales Channels
12.2.2 Neuroendocrine Carcinoma Drugs Distributors
12.3 Neuroendocrine Carcinoma Drugs Customers
13 Estimates and Projections by Regions (2021-2026)
13.1 Global Neuroendocrine Carcinoma Drugs Sales Forecast (2021-2026)
13.1.1 Global Neuroendocrine Carcinoma Drugs Sales Forecast by Regions (2021-2026)
13.1.2 Global Neuroendocrine Carcinoma Drugs Revenue Forecast by Regions (2021-2026)
13.2 North America Market Size Forecast (2021-2026)
13.2.1 North America Neuroendocrine Carcinoma Drugs Sales Forecast (2021-2026)
13.2.2 North America Neuroendocrine Carcinoma Drugs Revenue Forecast (2021-2026)
13.2.3 North America Neuroendocrine Carcinoma Drugs Size Forecast by County (2021-2026)
13.3 Europe Market Size Forecast (2021-2026)
13.3.1 Europe Neuroendocrine Carcinoma Drugs Sales Forecast (2021-2026)
13.3.2 Europe Neuroendocrine Carcinoma Drugs Revenue Forecast (2021-2026)
13.3.3 Europe Neuroendocrine Carcinoma Drugs Size Forecast by County (2021-2026)
13.4 Asia Pacific Market Size Forecast (2021-2026)
13.4.1 Asia Pacific Neuroendocrine Carcinoma Drugs Sales Forecast (2021-2026)
13.4.2 Asia Pacific Neuroendocrine Carcinoma Drugs Revenue Forecast (2021-2026)
13.4.3 Asia Pacific Neuroendocrine Carcinoma Drugs Size Forecast by Region (2021-2026)
13.5 Latin America Market Size Forecast (2021-2026)
13.5.1 Latin America Neuroendocrine Carcinoma Drugs Sales Forecast (2021-2026)
13.5.2 Latin America Neuroendocrine Carcinoma Drugs Revenue Forecast (2021-2026)
13.5.3 Latin America Neuroendocrine Carcinoma Drugs Size Forecast by County (2021-2026)
13.6 Middle East and Africa Market Forecast
13.6.1 Middle East and Africa Neuroendocrine Carcinoma Drugs Sales Forecast (2021-2026)
13.6.2 Middle East and Africa Neuroendocrine Carcinoma Drugs Revenue Forecast (2021-2026)
13.6.3 Middle East and Africa Neuroendocrine Carcinoma Drugs Size Forecast by County (2021-2026)
14 Research Findings and Conclusion
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
【掲載企業】
Xiaflex、Novartis AG、Roche、Molecular Insight pharmaceuticals、Callisto Pharmaceuticals
【免責事項】
https://www.globalresearch.jp/disclaimer